[PDF][PDF] Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC …
…, JP Julien, IS Fentiman, R Agresti… - Journal of clinical …, 2013 - researchgate.net
… Fentiman, Roberto Agresti, Philippe Rouanet, Christine Tunon de Lara, Harry Bartelink, Nicole
Duez, Emiel JT Rutgers, and Nina Bijker … tal, London, United Kingdom; and Roberto Agresti …
Duez, Emiel JT Rutgers, and Nina Bijker … tal, London, United Kingdom; and Roberto Agresti …
HER2 as a prognostic factor in breast cancer
S Ménard, S Fortis, F Castiglioni, R Agresti, A Balsari - Oncology, 2001 - karger.com
HER2 amplification/overexpression is a marker of poor prognosis in breast cancer. The
prognostic impact of HER2 positivity is lower in node-negative compared with node-positive …
prognostic impact of HER2 positivity is lower in node-negative compared with node-positive …
[HTML][HTML] Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study
Background Survival differences across Europe for patients with cancers of breast, uterus,
cervix, ovary, vagina and vulva have been documented by previous EUROCARE studies. In …
cervix, ovary, vagina and vulva have been documented by previous EUROCARE studies. In …
Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND …
…, C Sangalli, V Galimberti, M Porpiglia, R Agresti… - JAMA …, 2023 - jamanetwork.com
Importance Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node
staging of patients with early breast cancer (BC), but its necessity can be questioned since …
staging of patients with early breast cancer (BC), but its necessity can be questioned since …
Role of HER2 in wound-induced breast carcinoma proliferation
E Tagliabue, R Agresti, ML Carcangiu, C Ghirelli… - The Lancet, 2003 - thelancet.com
Objective Clinical and experimental data have suggested that surgical removal of primary
tumours promotes the growth of metastatic lesions. We assessed the effect of surgery on …
tumours promotes the growth of metastatic lesions. We assessed the effect of surgery on …
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast …
F Crippa, E Seregni, R Agresti, C Chiesa… - European journal of …, 1998 - Springer
To investigate the possible role of positron emission tomography (PET) with fluorine-18
fluorodeoxyglucose (FDG) in the prognostic evaluation of primary breast cancer, we studied 86 …
fluorodeoxyglucose (FDG) in the prognostic evaluation of primary breast cancer, we studied 86 …
[HTML][HTML] Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up
…, G Vetrella, AM Cerrotta, D Piromalli, R Agresti - Annals of surgical …, 2011 - Springer
Objective To assess the long-term safety of no axillary clearance in elderly patients with
breast cancer and nonpalpable axillary nodes. Background Lymph node evaluation in elderly …
breast cancer and nonpalpable axillary nodes. Background Lymph node evaluation in elderly …
Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-d-glucose–Positron Emission Tomography: Clinical Evaluation and Alternative Management
M Greco, F Crippa, R Agresti, E Seregni… - Journal of the …, 2001 - academic.oup.com
Background: Surgical removal of axillary lymph node and histologic examination for metastases
are used to determine whether adjuvant treatment is necessary for patients with breast …
are used to determine whether adjuvant treatment is necessary for patients with breast …
Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial
…, I Ardoino, L Lozza, S Bohm, G Vetrella, R Agresti - 2012 - journals.lww.com
Objective: To assess the role of axillary dissection in older breast cancer patients with a
clinically clear axilla. Background: Axillary dissection, once standard treatment for breast cancer, …
clinically clear axilla. Background: Axillary dissection, once standard treatment for breast cancer, …
Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis
M Greco, R Agresti, N Cascinelli, P Casalini… - Annals of …, 2000 - journals.lww.com
Objective To evaluate the impact of breast carcinoma (T1–2N0) surgery without axillary
dissection on axillary and distant relapses, and to evaluate the usefulness of a panel of …
dissection on axillary and distant relapses, and to evaluate the usefulness of a panel of …